Peer-reviewedCC BYThe Journal of clinical investigation
The genomic afterlife of cancer therapy.
4 affiliations
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- 2Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- 3Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.
- 4Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Related
- Neoadjuvant Chemotherapy Increases Genomic Radioresistance in Hormone Receptor–positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Implications for Radiation Sensitivity Index/Genomic-Adjusted Radiation Dose–Guided Radiation Therapy Personalization
- Prediction of Tumor Complete Response Using Genomic and Clinical Data in Solid Cancer Undergoing Definitive Radiation Therapy
- Multifocal ground-glass opacities in lung cancer: a narrative review of genomic evolution, immune ecology, and biology-informed clinical management
- Chronic Cigarette Smoke Extract Exposure Promotes Genomic and Phenotypic Reprogramming in Lung Cancer Cells
- Integrated Genomic and Immune Profiling Reveals PIK3CA-Mutant HPV16-Positive Cervical Cancer as a Clinically Aggressive and Immunologically Distinct Subtype in Patients from Eastern India
BibTeX
@article{wang2026genomic,
title = {{The genomic afterlife of cancer therapy.}},
author = {Xiaolu Wang and Nilay S Sethi},
journal = {The Journal of clinical investigation},
year = {2026},
month = nov,
doi = {10.1172/jci213544},
url = {https://europepmc.org/article/MED/42969227},
note = {CC BY},
}
RIS
TY - JOUR
TI - The genomic afterlife of cancer therapy.
AU - Xiaolu Wang
AU - Nilay S Sethi
PY - 2026
DA - 2026/11/02
JO - The Journal of clinical investigation
DO - 10.1172/jci213544
UR - https://europepmc.org/article/MED/42969227
SN - 0021-9738
SN - 1558-8238
ER -